Latest ArticlesEN-USSat, 26 May 2018 15:32:29 -0400966671
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pI8jxJuM-sE/notable-two-hundred-day-moving-average-cross-icpt-cm966671
Notable Two Hundred Day Moving Average Cross - ICPTIn trading on Monday shares of Intercept Pharmaceuticals Inc Symbol ICPT crossed below their 200 day moving average of 70 70 changing hands as low as 69 92 per share Intercept Pharmaceuticals Inc shares are currently trading down about 3 2 on the day The chart below shows the one<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/pI8jxJuM-sE" height="1" width="1" alt=""/>Mon, 21 May 2018 22:43:15 Z2018-05-21T22:43:15Zhttps://www.nasdaq.com/article/notable-two-hundred-day-moving-average-cross-icpt-cm966671965821
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YDimj5h5dcg/notable-friday-option-activity-icpt-jnj-celg-cm965821
Notable Friday Option Activity: ICPT, JNJ, CELGAmong the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Intercept Pharmaceuticals Inc Symbol ICPT where a total of 2 421 contracts have traded so far representing approximately 242 100 underlying shares That amounts to about 49 4<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/YDimj5h5dcg" height="1" width="1" alt=""/>Fri, 18 May 2018 21:26:37 Z2018-05-18T21:26:37Zhttps://www.nasdaq.com/article/notable-friday-option-activity-icpt-jnj-celg-cm965821961516
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/toRJXPhxc8M/analysts-anticipate-14-upside-for-fxh-cm961516
Analysts Anticipate 14% Upside For FXHLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/toRJXPhxc8M" height="1" width="1" alt=""/>Thu, 10 May 2018 13:32:19 Z2018-05-10T13:32:19Zhttps://www.nasdaq.com/article/analysts-anticipate-14-upside-for-fxh-cm961516961285
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qupRgGfF37E/intercept-pharmaceuticals-icpt-shares-cross-above-200-dma-cm961285
Intercept Pharmaceuticals (ICPT) Shares Cross Above 200 DMAIn trading on Wednesday shares of Intercept Pharmaceuticals Inc Symbol ICPT crossed above their 200 day moving average of 72 75 changing hands as high as 72 78 per share Intercept Pharmaceuticals Inc shares are currently trading up about 2 6 on the day The chart below shows the one<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/qupRgGfF37E" height="1" width="1" alt=""/>Wed, 09 May 2018 22:32:03 Z2018-05-09T22:32:03Zhttps://www.nasdaq.com/article/intercept-pharmaceuticals-icpt-shares-cross-above-200-dma-cm961285960151
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KD3xymy4XZg/intercept-icpt-q1-loss-narrower-than-expected-sales-lag-cm960151
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales LagIntercept Pharmaceuticals Inc ICPT reported mixed results for first quarter 2018 The company reported a loss of 3 22 per share in the first quarter narrower than the Zacks Consensus Estimate of a loss of 3 41 per share and the year ago loss of 3 61 per share<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/KD3xymy4XZg" height="1" width="1" alt=""/>Tue, 08 May 2018 15:35:52 Z2018-05-08T15:35:52Zhttps://www.nasdaq.com/article/intercept-icpt-q1-loss-narrower-than-expected-sales-lag-cm960151959997
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7Nh55pgsRb4/earnings-reaction-history-intercept-pharm-583-follow-through-indicator-49-sensitive-cm959997
Earnings Reaction History: INTERCEPT PHARM, 58.3% Follow-Through Indicator, 4.9% SensitiveExpected Earnings Release 05 08 2018 PremarketExpected Earnings Release 05 08 2018 Premarket Avg Extended Hours Dollar Volume 895 650Avg Extended Hours Dollar Volume 895 650 INTERCEPT PHARM ICPT is due to issue its quarterly earnings report in the upcoming extended hours<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/7Nh55pgsRb4" height="1" width="1" alt=""/>Tue, 08 May 2018 11:51:16 Z2018-05-08T11:51:16Zhttps://www.nasdaq.com/article/earnings-reaction-history-intercept-pharm-583-follow-through-indicator-49-sensitive-cm959997956012
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QQzCKpjvRSs/whats-in-store-for-intercept-icpt-this-earnings-season-cm956012
What's in Store for Intercept (ICPT) This Earnings Season?Intercept Pharmaceuticals Inc ICPT is expected to report first quarter 2018 results on May 3 In the last reported quarter the company incurred a wider than expected loss Let s see how things are shaping up for this announcement Intercept s stock has gained 11 9 in the last six<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/QQzCKpjvRSs" height="1" width="1" alt=""/>Tue, 01 May 2018 00:06:54 Z2018-05-01T00:06:54Zhttps://www.nasdaq.com/article/whats-in-store-for-intercept-icpt-this-earnings-season-cm956012949611
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mf8WvQKBUpU/noteworthy-etf-outflows-xbi-avxs-once-icpt-cm949611
Noteworthy ETF Outflows: XBI, AVXS, ONCE, ICPTLooking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 177 6 million dollar outflow that s a 3 6 decrease week over week from 54 200 000<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Mf8WvQKBUpU" height="1" width="1" alt=""/>Wed, 18 Apr 2018 16:14:16 Z2018-04-18T16:14:16Zhttps://www.nasdaq.com/article/noteworthy-etf-outflows-xbi-avxs-once-icpt-cm949611948725
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w2387IO31Lk/intercept-reports-phase-iii-sub-study-liver-biopsy-data-cm948725
Intercept Reports Phase III Sub-Study Liver Biopsy DataIntercept Pharmaceuticals ICPT announced encouraging data from the POISE biopsy sub study Results from the study confirmed that long term treatment with obeticholic acid OCA leads to the reversal or stabilization of fibrosis cirrhosis in patients with primary biliary cholangitis PBC<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/w2387IO31Lk" height="1" width="1" alt=""/>Tue, 17 Apr 2018 00:11:55 Z2018-04-17T00:11:55Zhttps://www.nasdaq.com/article/intercept-reports-phase-iii-sub-study-liver-biopsy-data-cm948725948475
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V98ib-L_7zc/gilead-gild-presents-encouraging-data-on-nash-therapies-cm948475
Gilead (GILD) Presents Encouraging Data on NASH TherapiesGilead Sciences Inc GILD announced encouraging data from a proof of concept study of experimental combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis NASH The data were presented at The International Liver Congress 2018 in Paris<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/V98ib-L_7zc" height="1" width="1" alt=""/>Mon, 16 Apr 2018 17:12:28 Z2018-04-16T17:12:28Zhttps://www.nasdaq.com/article/gilead-gild-presents-encouraging-data-on-nash-therapies-cm948475947855
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-W4dy734zaU/health-care-sector-update-for-04132018-cdnaplseipctingn-cm947855
Health Care Sector Update for 04/13/2018: CDNA,PLSE,IPCT,INGNTop Health Care StocksTop Health Care Stocks JNJ 0 02 JNJ 0 02 PFE 0 00 PFE 0 00 ABT 0 24 ABT 0 24 MRK 0 64 MRK 0 64 AMGN 0 39 AMGN 0 39 Health care stocks were unable to sustain small gains from earlier in Friday s session with the NYSE Health Care Index sinking almost 0 4<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-W4dy734zaU" height="1" width="1" alt=""/>Fri, 13 Apr 2018 20:31:35 Z2018-04-13T20:31:35Zhttps://www.nasdaq.com/article/health-care-sector-update-for-04132018-cdnaplseipctingn-cm947855947811
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zvj9J06bCK0/health-care-sector-update-for-04132018-plseipctingn-cm947811
Health Care Sector Update for 04/13/2018: PLSE,IPCT,INGNTop Health Care StocksTop Health Care Stocks JNJ 0 01 JNJ 0 01 PFE 0 26 PFE 0 26 ABT 0 48 ABT 0 48 MRK 0 55 MRK 0 55 AMGN 0 58 AMGN 0 58 Health care stocks were narrowly higher in recent trade including a 0 1 gain for the NYSE Health Care Index reversing an equal sized<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Zvj9J06bCK0" height="1" width="1" alt=""/>Fri, 13 Apr 2018 18:31:27 Z2018-04-13T18:31:27Zhttps://www.nasdaq.com/article/health-care-sector-update-for-04132018-plseipctingn-cm947811947787
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ATThnAKOk5k/bristol-myers-collaborates-with-harvard-fibrosis-network-cm947787
Bristol-Myers Collaborates With Harvard Fibrosis NetworkBristol Myers Squibb Company BMY entered into a research collaboration agreement with Harvard Fibrosis Network of the Harvard Stem Cell Institute Both companies have teamed up to discover and develop potential new therapies for fibrotic diseases including fibrosis of the liver and heart<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ATThnAKOk5k" height="1" width="1" alt=""/>Fri, 13 Apr 2018 18:11:18 Z2018-04-13T18:11:18Zhttps://www.nasdaq.com/article/bristol-myers-collaborates-with-harvard-fibrosis-network-cm947787946006
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wK3zhYJvKes/tuesday-410-insider-buying-report-icpt-kmx-cm946006
Tuesday 4/10 Insider Buying Report: ICPT, KMXAs the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys At Intercept Pharmaceuticals ICPT a filing with the SEC revealed that on Monday<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/wK3zhYJvKes" height="1" width="1" alt=""/>Tue, 10 Apr 2018 16:09:04 Z2018-04-10T16:09:04Zhttps://www.nasdaq.com/article/tuesday-410-insider-buying-report-icpt-kmx-cm946006945351
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L9PSJIZfwGY/the-math-shows-iyy-can-go-to-152-cm945351
The Math Shows IYY Can Go To $152Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/L9PSJIZfwGY" height="1" width="1" alt=""/>Mon, 09 Apr 2018 15:24:40 Z2018-04-09T15:24:40Zhttps://www.nasdaq.com/article/the-math-shows-iyy-can-go-to-152-cm945351